Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2026 03:30 ET | Source: Kainova Therapeutics

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

Kainova Therapeutics has dosed the first European patient in its Phase I/II DOMISOL trial of DT-7012, advancing its Treg-depleting immunotherapy program.